Target Now Colon

Choosing a cancer therapy is one of the most important decisions a patient and a treating physician will make. The Target Now Colon℠ test from Caris Life Sciences™ can help. Target Now Colon is comprised of a series of tests that provide information for selecting a colorectal cancer therapy. The test examines key biomarkers inside the patient's tumor and suggests potential therapies that are likely to be successful.

Target Now Colon results are analyzed using published findings from clinical research by thousands of the world’s leading cancer researchers. After the analysis is finished, Target Now Colon provides the patient and the treating physician with a list of potential therapies to discuss.

For example, one of the biomarkers known to influence the course of colorectal cancer therapy is EGFR. In the past, all EGFR-positive tumors were treated with anti-EGFR medications. This approach seemed simple and straightforward. However, a subset of EGFR-positive patients do not respond to anti-EGFR medications. Research led to the discovery of a mutation in a gene called KRAS. This KRAS mutation was responsible for the poor therapeutic response seen in these patients. Now, prior to recommending anti-EGFR therapies, pathologists look for the presence of the mutated KRAS gene.

The enhanced information and detailed analysis from Target Now Colon can help patients and their treating physicians make better, more informed treatment decisions.